These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34652144)

  • 1. Sweet Drugs for Bad Bugs: A Glycomimetic Strategy against the DC-SIGN-Mediated Dissemination of SARS-CoV-2.
    Cramer J; Lakkaichi A; Aliu B; Jakob RP; Klein S; Cattaneo I; Jiang X; Rabbani S; Schwardt O; Zimmer G; Ciancaglini M; Abreu Mota T; Maier T; Ernst B
    J Am Chem Soc; 2021 Oct; 143(42):17465-17478. PubMed ID: 34652144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation.
    Beirag N; Kumar C; Madan T; Shamji MH; Bulla R; Mitchell D; Murugaiah V; Neto MM; Temperton N; Idicula-Thomas S; Varghese PM; Kishore U
    Front Immunol; 2022; 13():960733. PubMed ID: 35967323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly-l-lysine Glycoconjugates Inhibit DC-SIGN-mediated Attachment of Pandemic Viruses.
    Cramer J; Aliu B; Jiang X; Sharpe T; Pang L; Hadorn A; Rabbani S; Ernst B
    ChemMedChem; 2021 Aug; 16(15):2345-2353. PubMed ID: 34061468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist.
    Thépaut M; Luczkowiak J; Vivès C; Labiod N; Bally I; Lasala F; Grimoire Y; Fenel D; Sattin S; Thielens N; Schoehn G; Bernardi A; Delgado R; Fieschi F
    PLoS Pathog; 2021 May; 17(5):e1009576. PubMed ID: 34015061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combating DC-SIGN-mediated SARS-CoV-2 dissemination by glycan-mimicking polymers.
    Cramer J; Jiang X; Aliu B; Ernst B
    Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300396. PubMed ID: 38086006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C
    Patino-Alonso J; Cabrera-González J; Merino J; Nieto-Ortiz G; Lasala F; Katati J; da Cruz CHB; Monnappa AK; Mateos-Gil P; Canales Á; López-Montero I; Illescas BM; Delgado R; Martín N
    Small; 2024 May; 20(19):e2307045. PubMed ID: 38100142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycomimetic ligands block the interaction of SARS-CoV-2 spike protein with C-type lectin co-receptors.
    Pollastri S; Delaunay C; Thépaut M; Fieschi F; Bernardi A
    Chem Commun (Camb); 2022 Apr; 58(33):5136-5139. PubMed ID: 35380569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective targeting of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) with mannose-based glycomimetics: synthesis and interaction studies of bis(benzylamide) derivatives of a pseudomannobioside.
    Varga N; Sutkeviciute I; Guzzi C; McGeagh J; Petit-Haertlein I; Gugliotta S; Weiser J; Angulo J; Fieschi F; Bernardi A
    Chemistry; 2013 Apr; 19(15):4786-97. PubMed ID: 23417900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The S1 spike protein of SARS-CoV-2 upregulates the ERK/MAPK signaling pathway in DC-SIGN-expressing THP-1 cells.
    Johnson EL; Ohkawa Y; Kanto N; Fujinawa R; Kuribara T; Miyoshi E; Taniguchi N
    Cell Stress Chaperones; 2024 Apr; 29(2):227-234. PubMed ID: 38453000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of DC-SIGN as a trans-receptor in infection by MERS-CoV.
    Labiod N; Luczkowiak J; Tapia MM; Lasala F; Delgado R
    Front Cell Infect Microbiol; 2023; 13():1177270. PubMed ID: 37808906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique DC-SIGN clustering activity of a small glycomimetic: A lesson for ligand design.
    Sutkeviciute I; Thépaut M; Sattin S; Berzi A; McGeagh J; Grudinin S; Weiser J; Le Roy A; Reina JJ; Rojo J; Clerici M; Bernardi A; Ebel C; Fieschi F
    ACS Chem Biol; 2014 Jun; 9(6):1377-85. PubMed ID: 24749535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus.
    Kondo Y; Larabee JL; Gao L; Shi H; Shao B; Hoover CM; McDaniel JM; Ho YC; Silasi-Mansat R; Archer-Hartmann SA; Azadi P; Srinivasan RS; Rezaie AR; Borczuk A; Laurence JC; Lupu F; Ahamed J; McEver RP; Papin JF; Yu Z; Xia L
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34291736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noncarbohydrate glycomimetics and glycoprotein surrogates as DC-SIGN antagonists and agonists.
    Prost LR; Grim JC; Tonelli M; Kiessling LL
    ACS Chem Biol; 2012 Sep; 7(9):1603-8. PubMed ID: 22747463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical Study of SARS-CoV-2 Viral Entry Factors in the Cornea and Ocular Surface.
    Roehrich H; Yuan C; Hou JH
    Cornea; 2020 Dec; 39(12):1556-1562. PubMed ID: 32826650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New lipophilic glycomimetic DC-SIGN ligands: Stereoselective synthesis and SPR-based binding inhibition assays.
    Di Pietro S; Bordoni V; Iacopini D; Achilli S; Pineschi M; Thépaut M; Fieschi F; Crotti P; Di Bussolo V
    Bioorg Chem; 2021 Feb; 107():104566. PubMed ID: 33387733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and quantitative analysis of two independent binding modes of a small ligand responsible for DC-SIGN clustering.
    Guzzi C; Alfarano P; Sutkeviciute I; Sattin S; Ribeiro-Viana R; Fieschi F; Bernardi A; Weiser J; Rojo J; Angulo J; Nieto PM
    Org Biomol Chem; 2016 Jan; 14(1):335-44. PubMed ID: 26611567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unprecedented Thiacalixarene Fucoclusters as Strong Inhibitors of Ebola cis-Cell Infection and HCMV-gB Glycoprotein/DC-SIGN C-type Lectin Interaction.
    Taouai M; Porkolab V; Chakroun K; Cheneau C; Luczkowiak J; Abidi R; Lesur D; Cragg PJ; Halary F; Delgado R; Fieschi F; Benazza M
    Bioconjug Chem; 2019 Apr; 30(4):1114-1126. PubMed ID: 30912645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monovalent mannose-based DC-SIGN antagonists: targeting the hydrophobic groove of the receptor.
    Tomašić T; Hajšek D; Švajger U; Luzar J; Obermajer N; Petit-Haertlein I; Fieschi F; Anderluh M
    Eur J Med Chem; 2014 Mar; 75():308-26. PubMed ID: 24556146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of a glycomimetic ligand in the carbohydrate recognition domain of C-type lectin DC-SIGN. Structural requirements for selectivity and ligand design.
    Thépaut M; Guzzi C; Sutkeviciute I; Sattin S; Ribeiro-Viana R; Varga N; Chabrol E; Rojo J; Bernardi A; Angulo J; Nieto PM; Fieschi F
    J Am Chem Soc; 2013 Feb; 135(7):2518-29. PubMed ID: 23360500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of DC-SIGN-mediated trans infection of T cells by mannose-binding lectin.
    Spear GT; Zariffard MR; Xin J; Saifuddin M
    Immunology; 2003 Sep; 110(1):80-5. PubMed ID: 12941144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.